SCHEMBL15069736

SCHEMBL15069736

CC(C)(C)OC(=O)N1CC[C@H](Oc2ccc3ccc(=O)oc3c2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.48
ALDH1A1 P00352 4/20 0.48
TSHR P16473 1/20 0.48
HSD17B10 Q99714 1/20 0.48
GPR119 Q8TDV5 4/20 0.47
USP30 Q70CQ3 1/20 0.46
GLA P06280 4/20 0.46
GAA P10253 4/20 0.46
MAPT P10636 2/20 0.46
HPGD P15428 2/20 0.46
HIF1A Q16665 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
CA12 O43570 1/20 0.44
POLB P06746 1/20 0.44
CA9 Q16790 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
KMT2A Q03164 1/20 0.44
MAOA P21397 1/20 0.44
CHEK2 O96017 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15065810 1.00 KDM4E (0.48) KDM4EALDH1A1TSHRHSD17B10GPR119
SCHEMBL15065843 0.86 GPR119 (0.46) GPR119USP30HRH3MAOACHEK2
SCHEMBL15086426 0.86 GPR119 (0.46) GPR119USP30HRH3MAOACHEK2
SCHEMBL15066487 0.82 MAOB (0.50) GPR119USP30MAOA
SCHEMBL15066485 0.82 MAOB (0.50) GPR119USP30MAOA
SCHEMBL1011111 0.81 MAOA (0.47) KDM4EALDH1A1TSHRHSD17B10GPR119
SCHEMBL15086448 0.81 KDM4E (0.52) KDM4EALDH1A1TSHRHSD17B10GPR119
SCHEMBL15086427 0.80 MAOB (0.54) KDM4EALDH1A1HSD17B10GPR119GLA
SCHEMBL16669628 0.80 MAOB (0.54) KDM4EALDH1A1HSD17B10GPR119GLA
SCHEMBL1949495 0.80 MAOA (0.47) KDM4EALDH1A1TSHRHSD17B10GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE47689-E1 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2019-11-05 US disclosed
EP-2797592-B1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS INC (US) 2019-08-28 EP disclosed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 US disclosed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 US disclosed
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-30 US disclosed
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-30 US disclosed
EP-2797592-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2014-11-05 EP disclosed
WO-2013101974-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-07-04 WO disclosed
WO-2013101974-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, RBM17, RBM22 KDM4E 829/4885ALDH1A1 1006/4885TSHR 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.